DE69233169D1 - Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. - Google Patents

Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.

Info

Publication number
DE69233169D1
DE69233169D1 DE69233169T DE69233169T DE69233169D1 DE 69233169 D1 DE69233169 D1 DE 69233169D1 DE 69233169 T DE69233169 T DE 69233169T DE 69233169 T DE69233169 T DE 69233169T DE 69233169 D1 DE69233169 D1 DE 69233169D1
Authority
DE
Germany
Prior art keywords
human
compound
tumor
topotecan
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233169T
Other languages
English (en)
Other versions
DE69233169T2 (de
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69233169D1 publication Critical patent/DE69233169D1/de
Publication of DE69233169T2 publication Critical patent/DE69233169T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69233169T 1991-11-15 1992-11-13 Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. Expired - Lifetime DE69233169T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79304191A 1991-11-15 1991-11-15
US793041 1991-11-15
PCT/US1992/009864 WO1993009782A1 (en) 1991-11-15 1992-11-13 Combination chemotherapy

Publications (2)

Publication Number Publication Date
DE69233169D1 true DE69233169D1 (de) 2003-09-25
DE69233169T2 DE69233169T2 (de) 2004-05-27

Family

ID=25158913

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233169T Expired - Lifetime DE69233169T2 (de) 1991-11-15 1992-11-13 Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.

Country Status (15)

Country Link
US (1) US5633016A (de)
EP (3) EP1393729A3 (de)
JP (1) JPH07501079A (de)
AT (1) ATE247471T1 (de)
AU (1) AU671605B2 (de)
CA (1) CA2123321C (de)
DE (1) DE69233169T2 (de)
DK (1) DK0612248T3 (de)
ES (1) ES2204894T3 (de)
HK (1) HK1012268A1 (de)
MX (1) MX9206577A (de)
NZ (1) NZ245112A (de)
PT (1) PT101061B (de)
WO (1) WO1993009782A1 (de)
ZA (1) ZA928771B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
AU671605B2 (en) * 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
DE69435084T2 (de) * 1993-01-15 2009-03-19 The Stehlin Foundation For Cancer Research, Houston Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
AU715527B2 (en) * 1995-06-27 2000-02-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
WO2000054839A2 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
EP2289549A3 (de) 1999-10-01 2011-06-15 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US6849599B2 (en) 2000-03-08 2005-02-01 Rhode Island Hospital Combination drug therapy
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2003075952A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
CA2818693C (en) 2002-08-12 2016-05-17 Jennerex, Inc. Methods and compositions concerning poxviruses and cancer
US20060134801A1 (en) * 2003-03-03 2006-06-22 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
AU2006249199A1 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
CN101351213B (zh) * 2005-09-07 2013-10-02 詹纳里克斯公司 使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
CN101998851A (zh) * 2008-02-08 2011-03-30 帕纳德制药公司 吡铂和西妥昔单抗治疗结直肠癌的用途
EP3409119B1 (de) 2009-09-14 2020-08-12 SillaJen Biotherapeutics, Inc. Krebskombinationstherapie mit onkolytischem vaccinia virus
CA2802882C (en) 2010-06-18 2018-10-30 Jerry Lanchbury Methods and materials for assessing loss of heterozygosity
EP3109325B1 (de) 2010-08-24 2018-12-26 Dana-Farber Cancer Institute, Inc. Verfahren zur vorhersage der reaktion auf eine antikrebstherapie
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
JP6043729B2 (ja) * 2011-12-21 2016-12-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体
CA2860312C (en) 2011-12-21 2022-07-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2013130347A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
EP2859118B1 (de) 2012-06-07 2017-11-22 Institut Curie Verfahren zur detektion der deaktivierung des pfades der homologen rekombination (brca1/2) in menschlichen tumoren
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
US9821008B2 (en) * 2013-11-25 2017-11-21 The University Of Toledo Inhibitors of ERCC1-XPF and methods of using the same
ES2909899T3 (es) 2013-12-09 2022-05-10 Inst Curie Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
EP4141127A1 (de) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
EP0418099B1 (de) 1989-09-15 2001-12-19 Research Triangle Institute Verfahren zur herstellung von 10,11-Methylendioxy-20(RS)-Camptothecin und 10,11-Methylendioxy-20(S)-Camptothecin-Analog
AU671605B2 (en) * 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy

Also Published As

Publication number Publication date
EP0612248A1 (de) 1994-08-31
MX9206577A (es) 1993-05-01
EP1393729A2 (de) 2004-03-03
EP1393730A3 (de) 2004-03-17
US5633016A (en) 1997-05-27
JPH07501079A (ja) 1995-02-02
EP0612248B1 (de) 2003-08-20
DK0612248T3 (da) 2003-12-08
DE69233169T2 (de) 2004-05-27
EP1393730A2 (de) 2004-03-03
PT101061A (pt) 1994-06-30
CA2123321C (en) 2003-09-30
EP1393729A3 (de) 2004-03-17
CA2123321A1 (en) 1993-05-27
ATE247471T1 (de) 2003-09-15
ES2204894T3 (es) 2004-05-01
EP0612248A4 (en) 1996-05-08
NZ245112A (en) 1995-07-26
WO1993009782A1 (en) 1993-05-27
HK1012268A1 (en) 1999-07-30
AU671605B2 (en) 1996-09-05
ZA928771B (en) 1993-09-08
AU3137993A (en) 1993-06-15
PT101061B (pt) 1999-07-30

Similar Documents

Publication Publication Date Title
DE69233169D1 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
ATE195735T1 (de) Imidazo (4,5-c)pyridin-4-amine
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
IL104006A0 (en) Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them
IL89840A0 (en) Substituted flavonoid compounds and salts thereof,their preparation and pharmaceutical compositions containing them
EP0344880A3 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
ZA943553B (en) Tri(platinum) complexes
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
DE69233793D1 (de) Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs
HK1012267A1 (en) Use of topotecan in the treatment of non-small cell lung carcinoma
IL106289A (en) Phospholipid derivatives their preparation and pharmaceutical compositions containing them
MY105876A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer.
GB8819626D0 (en) Pharmaceutical composition for treatment of tumours
AU2582588A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
PT1250926E (pt) Utilização de uma s-camptotecina insolúvel em água, com um anel de lactona fechado, no fabrico de um medicamento para o tratamento do cancro do cólon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition